摘要
目的研究高血压（ＥＨ）患者外周血淋巴细胞β受体的变化特征及依那普利对ＥＨ伴左室肥厚（ＬＶＨ）患者外周血淋巴细胞β受体的影响。方法采用超声心动图与３Ｈ－双氢阿普洛尔（３Ｈ－ＤＨＡ）放射性配基结合分析法，测定６２例ＥＨ男性患者左室重量指数（ＬＶＭＩ）与外周血淋巴细胞β受体密度（βｍａｘ），３０例健康者予以同期测定，作为对照；其中２７例ＥＨ伴ＬＶＨ患者接受依那普利治疗１６周，于治疗后复测ＬＶＭＩ及βｍａｘ，并与治疗前予以对照。结果（１）ＥＨ组患者βｍａｘ为４９０±１０２ｆｍｏｌ／１０７ｃｅｌ，较正常对照组（３６７±１１０ｆｍｏｌ／１０７ｃｅｌ）明显上调（Ｐ＜０．０１）；（２）ＥＨ伴ＬＶＨ患者βｍａｘ为５９２±１０３ｆｍｏｌ／１０７ｃｅｌ，显著高于ＥＨ不伴ＬＶＨ患者（４０４±１０７ｆｍｏｌ／１０７ｃｅｌ，Ｐ＜０．０１）和正常对照组（３６７±１１０ｆｍｏｌ／１０７ｃｅｌ，Ｐ＜０．０１），而后两者之间βｍａｘ比较并无统计学差异（Ｐ＞０．０５）。（３）依那普利干预后ＥＨ伴ＬＶＨ患者βｍａｘ较前下降２３．１％±１０．３％（Ｐ＜０．０１），ＬＶＭＩ较前下降１８．６％±１０．１％（Ｐ＜０．０１），两者虽仍高于正常对照组（Ｐ＜０?
Aim To observe the changes of βadrenoreceptor in peripheral lymphocytes in patients of essential hypertensive(EH) with and without left ventricular hypertrophy (LVH). Methods βadrenoreceptor in peripheral lymphocytes was delected by 3Hdihydroalprenolol (3HDHA) radio ligand binding and left ventricular mass was measured by echocardiographic recordings and left ventricular mass index(LVMI) was calculated according to Devereux formula in 62 patients with EH. Twentyseven patients of EH with LVH were received treatment with enalapril for 16 weeks. Results (1)In patients with EH βmax was significantly higher than that in the control group(490±102 vs 367±110 fmol/107cell, P<001).(2)In patients of EH with LVH βmax was significantly higherthan that in patients of EH without LVH(592±103 vs 404±107 fmol/107cell, P<001) and the control group (592±103 vs 367±110 fmol/10cell, P<0001). There was no difference in β max between patients of EH without LVH and the control group,P>005).(3)LVMI was reduced significantly by 18±101%(P<001) and βmax lowered significantly by 231%±103%(P<001) after treatment with enalapril for 16 weeks. Conclusion β max was upregulated significantly in peripheral lymphocytes in patients of EH with LVH. Enalapril could significantly reduce left ventricular mass and downregulate βmax in peripheral lymphocytes in patients of EH with LVH.
出处
《高血压杂志》
CSCD
1998年第1期39-41,共3页
Chinese Journal of Hypertension
基金
河北省科委科研基金
关键词
高血压
左室肥厚
β受体.肾上腺素能
依那普利
hypertension
left ventricular hypertrophy
βadrenoreceptor
adrenergic
enalapril
